Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors

Abstract To optimally utilize therapeutic monoclonal antibodies in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) understanding their mechanisms of action and the factors influencing these mechanisms is required. We show strong correlations between target antigen expression levels and sensitivity to complement-dependent cytotoxicity (CDC) induced by rituximab, ofatumumab, or alemtuzumab in a panel of cell lines derived from primary B-ALL cells and in primary B-ALL samples. Simultaneous loss of expression of membrane-bound complement regulatory proteins (mCRP) CD55 and CD59 due to glycophosphatidylinositol-anchor deficiency, significantly increased sensitivity to CDC. Accordingly, induced increase in CD55 or CD59 expression protected cells against CDC. The extent of protection co-depended on antigen expression and antibody concentration. In contrast, natural variation in mCRP expression could not be used as a single factor to predict sensitivity to CDC. In conclusion, sensitivity of B-ALL cells to CDC was predominantly determined by antibody concentration and target antigen expression.

[1]  H. Dombret,et al.  Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[2]  M. Konopleva,et al.  Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL) , 2015 .

[3]  T. Chambers,et al.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. , 2015, Cancer research.

[4]  S. Mamidi,et al.  Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells , 2015, Oncoimmunology.

[5]  P. Lang,et al.  Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies , 2013, Front. Immunol..

[6]  M. Introna,et al.  Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy , 2013, The Journal of Immunology.

[7]  P. Parren,et al.  Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients , 2012, The Journal of Immunology.

[8]  Gongxiong Wu,et al.  Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. , 2011, Cancer research.

[9]  J. Falkenburg,et al.  A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. , 2010, Blood.

[10]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[12]  Ling-Juan Gao,et al.  Role of decay-accelerating factor in regulating survival of human cervical cancer cells , 2010, Journal of Cancer Research and Clinical Oncology.

[13]  H. Kantarjian,et al.  Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.

[14]  J. Falkenburg,et al.  Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. , 2009, Experimental hematology.

[15]  Jian Huang,et al.  A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma , 2008, Clinical Cancer Research.

[16]  C. Tripodo,et al.  In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. , 2007, Cancer research.

[17]  M. Cragg,et al.  Mechanisms of killing by anti-CD20 monoclonal antibodies. , 2007, Molecular immunology.

[18]  Anton Hagenbeek,et al.  Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity , 2006, Clinical Cancer Research.

[19]  G. Garcia-Manero,et al.  Activity of alemtuzumab in patients with CD52‐positive acute leukemia , 2006, Cancer.

[20]  T. Barbui,et al.  The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. , 2006, Haematologica.

[21]  S. Schichman,et al.  Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. , 2004, Leukemia research.

[22]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[23]  J. Falkenburg,et al.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. , 2004, Blood.

[24]  Michael E. Williams,et al.  Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1 , 2004, The Journal of Immunology.

[25]  M. A. van der Hoorn,et al.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. , 2003, Blood.

[26]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[27]  K. Busam,et al.  Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. , 2003, Blood.

[28]  R. Gressin,et al.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.

[29]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[30]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[31]  E. Erba,et al.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.

[32]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[33]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[34]  L. Tesson,et al.  PROTECTION OF RAT ENDOTHELIAL CELLS FROM PRIMATE COMPLEMENT‐MEDIATED LYSIS BY EXPRESSION OF HUMAN CD59 AND/OR DECAY‐ACCELERATING FACTOR , 1994, Transplantation.

[35]  T. Fujita,et al.  Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. , 1992, Journal of immunology.

[36]  T. The,et al.  Conjugation of fluorescein isothiocyanate to antibodies. I. Experiments on the conditions of conjugation. , 1970, Immunology.

[37]  T. The,et al.  Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. , 1970, Immunology.